(S)-N-BOC-2-氨基-4-甲基戊烷氰 | 172695-24-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-N-BOC-2-氨基-4-甲基戊烷氰
• 中文别名: (S)-N-逆丁氧羰基-2-氨基-3-甲基戊烷氰
• 英文名称: (S)-3-<(tert-butoxycarbonyl)amino>-5-methylhexanenitrile
• 英文别名: (S)-2-(N-t-butoxycarbonylamino)-4-methylpentyl cyanide；(S)-tert-butyl (1-cyano-4-methylpentan-2-yl)carbamate；tert-butyl (S)-(1-cyano-4-methylpentan-2-yl)carbamate；(3S)-3-(t-butoxycarbonylamino)-5-methylhexanenitrile；(S)-N-Boc-2-amino-4-methylpentyl cyanide；tert-butyl N-[(2S)-1-cyano-4-methylpentan-2-yl]carbamate
• CAS: 172695-24-8
• 化学式: C₁₂H₂₂N₂O₂
• 分子量: 226.319
• InChiKey: MBYHFWNDSROMGX-SNVBAGLBSA-N

物化性质

• 熔点：
  75-77 °C
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S36,S37
• 危险类别码：
  R20/21/22
• 储存条件：
  存于阴凉干燥处

SDS

Name:	(s)-n-boc-2-amino-4-methylpentyl cyanide Material Safety Data Sheet
Synonym:	(S)-N-tert-Butoxycarbonyl-2-amino-3-methylpentyl cyanide
CAS:	172695-24-8

Section 1 - Chemical Product MSDS Name: (s)-n-boc-2-amino-4-methylpentyl cyanide Material Safety Data Sheet
Synonym: (S)-N-tert-Butoxycarbonyl-2-amino-3-methylpentyl cyanide

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
172695-24-8	(S)-N-BOC-2-Amino-4-methylpentyl cyani		unlisted

+++++
Hazard Symbols: XN

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Harmful by inhalation, in contact with skin and if swallowed. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 172695-24-8: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 75 - 77 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: >250 deg C
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H22N2O2
Molecular Weight: 226,32

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 172695-24-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-N-BOC-2-Amino-4-methylpentyl cyanide - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and gloves. WGK (Water Danger/Protection) CAS# 172695-24-8: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 172695-24-8 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 172695-24-8 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 10/08/2004 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-N-BOC-2-氨基-4-甲基戊烷氰 在 盐酸 、 sodium hydroxide 作用下， 反应 14.5h， 生成 (S)-3-(benzyloxycarbonylamino)-5-methylhexanoic acid
  参考文献：
  名称：

  Chemoenzymatic Synthesis of 4-Amino-2-hydroxy Acids:  A Comparison of Mutant and Wild-Type Oxidoreductases

  摘要：

  We describe a new chemoenzymatic synthesis of enantiopure 4-amino-2-hydroxy acids using two biotransformations in a single-pot process in aqueous medium. These compounds are valuable as gamma-turn mimics for investigations into the secondary structure of peptides. The enzyme substrates are a series of carbobenzyloxy (CBZ)-protected 4-amino-2-keto esters, prepared efficiently from the L-amino acids, alanine, leucine, phenylalanine, and valine. First, the alpha-amino acids were converted to the corresponding beta-amino acids in a simple five-step procedure. A further one-carbon homologation via ozonolysis of the corresponding beta-keto cyanophosphoranes gave the required alpha-keto esters in good yield. The enzyme catalyzed hydrolyses of all the alpha-keto esters to the corresponding alpha-keto acids proceeded smoothly with the lipase from Candida rugosa. Using the same reaction pot, it was found that wild-type lactate dehydrogenases from either Bacillus stearothermophilus (BS-LDH) or Staphylococcus epidermidis (SE-LDH) could be used to specifically reduce the ketone of the alanine-derived alpha-keto acid 2, giving the (S)- and (R)-2-hydroxy acids, respectively, in good yields. However, the more bulky alpha-keto acids 3, 4, and 5 (derived from valine, leucine, and phenylalanine) were not substrates for these enzymes. In contrast, the genetically engineered H205Q mutant of D-hydroxyisocaproate dehydrogenase proved to be an ideal catalyst for the reduction of all the alpha-keto acids 2-5, giving excellent yields of the CBZ-protected (2R,4S)-4-amino-2-hydroxy acids as single diastereomers. This genetically engineered oxidoreductase has great potential value in synthesis due to its broad substrate specificity and high catalytic activity. For example, reduction of 1 mmol of N-protected (S)-4-amino-2-oxopentanoic acid 2 took just 4 h with the H205Q mutant giving, after esterification, the (R)-2-alcohol 25 in 85% yield, whereas with SE-LDH the reaction required 4 days to give a 67% yield of 25.

  DOI：

  10.1021/jo980821a
• 作为产物：
  描述：

  N-叔丁氧羰基-L-亮氨醇 在 咪唑 、 diphenylphosphinopolystyrene 、 碘 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (S)-N-BOC-2-氨基-4-甲基戊烷氰
  参考文献：
  名称：

  的对映体纯合成Ñ -and Ç -保护的均聚-β氨基酸由α氨基酸的直接同系¶

  摘要：

  对映纯的N和/或C保护的均-β-氨基酸可通过减少羧基官能团和转化所得的N-保护的，容易地且由具有相同侧链的N-保护的α-氨基酸以高收率制备。将β-氨基醇转化为相应的β-氨基碘化物，然后转化为β-氨基氰化物。这种策略的关键步骤是由对映体纯的合成表示Ñ -保护的β-氨基碘化物2和3被平稳地从母体氨基醇得到的1通过聚合物结合的三芳基膦-I 2 在无水二氯甲烷中的络合物。

  DOI：

  10.1016/0040-4020(95)00778-7

文献信息

• A Multifaceted Secondary Structure Mimic Based On Piperidine-piperidinones
  作者：Dongyue Xin、Lisa M. Perez、Thomas R. Ioerger、Kevin Burgess

  DOI：10.1002/anie.201400927

  日期：2014.4.1

  that with ideal secondary structures and real interface regions in PPIs. Scaffold 1 presents amino acid side‐chains that are quite separated from each other, in orientations that closely resemble ideal sheet or helical structures, similar non‐ideal structures at PPI interfaces, and regions of other PPI interfaces where the mimic conformation does not resemble any secondary structure. 68 different PPIs

  极简二级结构模拟物通常被制成类似于蛋白质-蛋白质相互作用 (PPI) 中的一个界面，从而扰乱它。我们最近提出合适的化学型可以直接与界面区域匹配，而无需考虑二级结构。在这里，我们描述了新化学型1的模块化合成，其溶液态构象集合的模拟，以及与理想二级结构和 PPI 中真实界面区域的相关性。脚手架1呈现彼此完全分离的氨基酸侧链，其方向与理想的片状或螺旋结构非常相似，在 PPI 界面具有相似的非理想结构，以及其他 PPI 界面的模拟构象与任何二级结构不相似的区域. 68 种不同的 PPI，其中1 个匹配孔的构象被识别。还提出了一种新方法来确定极简模拟晶体结构与其溶液构象的相关性。因此，dld - 1 faf以比最小能量溶液状态高0.91 kcal mol -1的构象结晶。
• Entropy-Controlled Catalytic Asymmetric 1,4-Type Friedel-Crafts Reaction of Phenols Using Conformationally Flexible Guanidine/Bisthiourea Organocatalyst
  作者：Yoshihiro Sohtome、Bongki Shin、Natsuko Horitsugi、Rika Takagi、Keiichi Noguchi、Kazuo Nagasawa

  DOI：10.1002/anie.201003172

  日期：——

  Soft and weak cooperation: Conformationally flexible organic compounds were found to promote the title transformation. These “soft” organocatalysts, which are able to control processes through the differential activation entropies (ΔΔS≠S−R) of the reactive intermediates, lead to high stereoselectivities without the requirement of fine‐tuning the reaction temperatures (see scheme).

  软弱合作：构象灵活的有机化合物可促进标题转换。这些“软”有机催化剂，其能够控制通过差动活化熵（ΔΔ过程小号≠小号- - [R ）的活性中间体导致高的立体选择性，而不微调反应温度的要求（见方案）。
• Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
  申请人：——

  公开号：US20040204368A1

  公开（公告）日：2004-10-14

  An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein all symbols have the same meaning as described in the specification. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system(s) disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的一种噁二唑衍生物及其非毒性盐， 其中所有符号的含义与规范中描述的相同。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗炎症性疾病、由细胞凋亡引起的疾病、由免疫反应紊乱引起的疾病、自身免疫疾病、由构成生物体的蛋白质分解引起的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌亢进等方面的药剂。
• Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
  申请人：——

  公开号：US20030166573A1

  公开（公告）日：2003-09-04

  An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein R is hydrogen, alkyl, CycA, etc.; AA 1 is a single bond, amino acid residue, etc.; AA 2 is a single bond, amino acid residue, etc.; R 7 and R 8 are hydrogen, alkyl, etc.; R 9 is hydrogen, alkyl, etc.; R 10 is hydrogen, alkyl, etc.). The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的一种噁二唑衍生物及其非毒性盐，其中R为氢、烷基、环烷A等；AA1为单键、氨基酸残基等；AA2为单键、氨基酸残基等；R7和R8为氢、烷基等；R9为氢、烷基等；R10为氢、烷基等。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗炎症性疾病、细胞凋亡诱导的疾病、免疫反应紊乱诱导的疾病、自身免疫疾病、由组成生物体的蛋白质分解诱导的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌虚弱等方面的药物。
• [EN] HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS SPIRO HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2022093856A1

  公开（公告）日：2022-05-05

  The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutantKRASprotein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.

  本公开提供具有抑制G12C突变KRAS蛋白活性的式（I）化合物。本公开还提供包含该化合物的药物组合物，用途和治疗某些疾病的方法，例如癌症，包括但不限于肺癌、胰腺癌和结直肠癌。